Ascelia Pharma AB (CHIX:ACES) Short Interest


CHIX:ACES Ascelia Pharma AB CHIX:ACES
37 GF Score
Price kr3.29
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:ACES vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Ascelia Pharma AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascelia Pharma AB Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's Short Interest falls into.


CHIX:ACES
37GF Score
Ascelia Pharma AB CHIX:ACES
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Business Description

Other Exchanges ACE:Sweden
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
37GF Score

Get the complete analysis for CHIX:ACES

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.29
Price